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Epoxyeicosatrienoic	acids	(EETs)	are	small	molecules	produced	by	cytochrome	P450	epoxygenases.	They	are	
lipid	mediators	that	act	as	autocrine	or	paracrine	factors	to	regulate	inflammation	and	vascular	tone.	As	a	
result,	drugs	that	raise	EET	levels	are	in	clinical	trials	for	the	treatment	of	hypertension	and	many	other	diseas-
es.	However,	despite	their	pleiotropic	effects	on	cells,	little	is	known	about	the	role	of	these	epoxyeicosanoids	in	
cancer.	Here,	using	genetic	and	pharmacological	manipulation	of	endogenous	EET	levels,	we	demonstrate	that	
EETs	are	critical	for	primary	tumor	growth	and	metastasis	in	a	variety	of	mouse	models	of	cancer.	Remarkably,	
we	found	that	EETs	stimulated	extensive	multiorgan	metastasis	and	escape	from	tumor	dormancy	in	several	
tumor	models.	This	systemic	metastasis	was	not	caused	by	excessive	primary	tumor	growth	but	depended	
on	endothelium-derived	EETs	at	the	site	of	metastasis.	Administration	of	synthetic	EETs	recapitulated	these	
results,	while	EET	antagonists	suppressed	tumor	growth	and	metastasis,	demonstrating	in	vivo	that	pharma-
cological	modulation	of	EETs	can	affect	cancer	growth.	Furthermore,	inhibitors	of	soluble	epoxide	hydro-
lase	(sEH),	the	enzyme	that	metabolizes	EETs,	elevated	endogenous	EET	levels	and	promoted	primary	tumor	
growth	and	metastasis.	Thus,	our	data	indicate	a	central	role	for	EETs	in	tumorigenesis,	offering	a	mechanis-
tic	link	between	lipid	signaling	and	cancer	and	emphasizing	the	critical	importance	of	considering	possible	
effects	of	EET-modulating	drugs	on	cancer.
Introduction
Endogenously produced lipid autacoids are locally acting small 
molecule mediators that play a central role in inflammation and in 
the response to tissue injury. Although these autacoids, including 
prostaglandins and leukotrienes, are best known as products of 
arachidonic acid metabolism by cyclooxygenases and lipoxygen-
ases (1), arachidonic acid is also a substrate for the cytochrome 
P450 (CYP) epoxygenases CYP2C8 and CYP2J2, which convert it 
to 4 regioisomeric EETs (5,6-EET, 8,9-EET, 11,12-EET, and 14,15-
EET). The bioactive EETs are produced predominantly in the 
endothelium and are metabolized by soluble epoxide hydrolase 
(sEH) to less-active dihydroxyeicosatrienoic acids (DHETs) (2, 3) 
(see scheme in Supplemental Figure 1A; supplemental material 
available online with this article; doi:10.1172/JCI58128DS1). EETs 
have been investigated as autocrine and paracrine mediators of 
arachidonic acid–induced vasorelaxation in the cardiovascular and 
renal systems. Thus, inhibitors of sEH, which raise endogenous 
EET levels, are in clinical trials as anti-hypertensive agents and are 
being considered for long-term use in diabetes, stroke, cerebral 
ischemia, dyslipidemia, pain, immunological disorders, eye dis-
eases, neurological diseases, renal disease, organ damage, vascular 
remodeling, atherosclerosis, ischemia-reperfusion, lung disease 
(chronic obstructive pulmonary disease [COPD]), graft stenosis, 
and other medical conditions (4, 5).
Despite their known proangiogenic effects (6–8), the role of EETs 
in cancer is poorly understood (9). CYP epoxygenases are regulated 
in human carcinoma tissues and tumor cell lines (10), and this has 
been associated with increased metastasis (11). Moreover, genetic 
polymorphisms in CYP2C8 and CYP2C9 influence disease-free 
survival of breast cancer patients (12). Thus, while existing studies 
associate CYP enzymes with cancer (10, 11, 13), the direct role of 
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their products, the EETs, in cancer remains unknown. Since EET 
levels are directly influenced by nutrients and inflammatory pro-
cesses (14), we investigated the effect of endothelium-derived and 
systemic EETs on cancer in a variety of animal models. We dem-
onstrate here that elevated EETs have a potent stimulatory effect 
on primary tumor growth and tumor angiogenesis. Surprisingly, 
elevated EETs triggered massive, unprecedented patterns of meta-
static spread and escape from tumor dormancy.
Results
Endothelium-derived EETs stimulate primary tumor growth. To deter-
mine whether EET autacoids produced by the endothelium pro-
mote cancer, we generated three lines of transgenic mice with high 
endothelial EET levels: mice with endothelial (Tie2 promoter– 
driven) expression of either human CYP2C8 or human CYP2J2 
(Tie2-CYP2C8-Tr, Tie2-CYP2J2-Tr) (15) and mice with global dis-
ruption of the gene that encodes sEH (sEH-null) (16). ECs isolated 
from Tie2-CYP2C8-Tr and Tie2-CYP2J2-Tr mice had significantly 
increased EET levels compared with ECs isolated from WT mice 
as measured by liquid chromatography–tandem mass spectrom-
etry (LC/MS/MS) (Supplemental Figure 1B), and sEH-null mice 
have significantly increased plasma EETs compared with WT 
mice (17). In contrast, cyclooxygenase and lipoxygenase metabo-
lites of arachidonic acid are unaffected in these mice. Conversely, 
to characterize the impact of reduced endothelial EET levels, we 
also used a novel murine model with endothelial expression of 
human sEH (Tie2-sEH-Tr) (18). ECs isolated from these mice had 
significantly decreased EET levels relative to ECs isolated from 
WT mice (Supplemental Figure 1B).
We first investigated whether EETs could stimulate primary 
tumor growth in a series of standard syngeneic tumor models 
using the genetically altered mice that exhibit high endothelial 
EET levels. We observed a dramatic increase in the growth of 
B16F10 melanoma, T241 fibrosarcoma, and Lewis lung carcino-
ma (LLC) in Tie2-CYP2C8-Tr, Tie2-CYP2J2-Tr, and sEH-null mice 
compared with WT mice, suggesting that endothelial EETs pro-
mote primary tumor growth (Figure 1A and Supplemental Figure 
1C). Conversely, in Tie2-sEH-Tr mice, there was a 60% reduction in 
B16F10 melanoma and T241 fibrosarcoma growth compared with 
WT mice, suggesting that tumor growth was suppressed in mice 
with low endothelial EET levels (Figure 1B).
Plasma 11,12-EET and 14-15-EET levels were elevated 15-fold 
in sEH-null tumor-bearing mice when measured on day 22 after 
injection of T241 fibrosarcoma (Supplemental Figure 1D). In Tie2-
CYP2C8-Tr mice, where enhanced EET biosynthesis was designed 
to be endothelium specific, plasma 14,15-EET increased by 33% 
on day 16 after injection of LLC (Supplemental Figure 1D). The 
changes in eicosanoid levels were selective for epoxyeicosanoids 
in that other eicosanoids and related metabolites (19) including 
PGE2, 6-keto PGF1α (stable PGI2 metabolite), PGD2, and several 
hydroxyeicosatetraenoic acid (HETE) regioisomers were not sig-
nificantly altered in these models (data not shown). LC/MS/MS 
analysis of T241 fibrosarcoma tumors from Tie2-CYP2C8-Tr, sEH-
null, and WT mice showed no changes in levels of EETs, including 
14,15-EET (Supplemental Figure 1E). Since both plasma EET lev-
els and primary tumor growth were increased in genetically altered 
mice, we reasoned that exogenously administrated EETs might 
also promote primary tumor growth in WT mice. Indeed, systemic 
administration of 14,15-EET by osmotic minipump significantly 
accelerated primary LLC tumor growth (Figure 1C).
To exclude the possibility that the tumor-stimulating effect 
of EETs was specific to the growth of subcutaneous tumors, we 
used an orthotopic human prostate cancer model (20). Systemic 
administration of 14,15-EET for 28 days to mice injected with 
human prostate cancer cells (PC3M-LN4) at an inoculation of 
10-fold fewer cells than normally used (20) stimulated orthotopic 
tumor growth (Supplemental Figure 1E). To further exclude that 
EETs promoted growth of these tumors via a specific beneficial 
effect on transplanted tumor cells, we next used an endogenous 
tumor model. Transgenic adenocarcinoma of the mouse prostate 
(TRAMP) mice are one of the few genetically engineered murine 
models of a spontaneous tumor that exhibits widespread metas-
tasis and closely mimics the histological progression of human 
prostate cancer (21). Plasma from TRAMP mice exhibited higher 
epoxygenase activity (sum of 14,15-EET and 14,15-DHET), 
while prostate tumors from TRAMP mice showed no change in 
14,15-EET levels relative to normal prostates from age-matched 
control mice (Supplemental Figure 1, G and H). Control mice at 
18 weeks of age (treated with vehicle for 13 weeks) had normal-
appearing prostates with intraepithelial neoplasia, while mice 
treated with 14,15-EET for 13 weeks showed large prostate tumors 
(Figure 1D). In summary, EETs promote tumor growth indepen-
dent of the specific tumor model used, ranging from subcutane-
ous and orthotopic transplantable to endogenous tumors.
EETs promote exit from tumor dormancy. Given that EETs stimu-
lated both endogenous and implanted tumors, we asked whether 
EETs quantitatively increase the growth rate of established tumors 
and/or accelerate the qualitative transition from a microscopic 
dormant tumor to a macroscopic growing tumor. This process is 
often termed escape from dormancy and is thought to be regu-
lated, in part, by the angiogenic switch as well as production of a 
critical mass of tumor-initiating cells (22, 23). Tumor dormancy 
is believed to be maintained by the suppression of angiogenesis 
(24, 25), while the triggers that initiate growth and angiogenesis 
of dormant tumor cells are poorly understood. We administered 
14,15-EET to mice injected with human liposarcoma cells derived 
from a clone previously shown to enter a stable period of dormancy 
(26). Here we observed that systemic administration of 14,15-EET 
for 113 days to mice injected with 10-fold fewer liposarcoma cells 
than normally required (26) led to macroscopic tumor growth by 
day 90 after tumor cell implantation (Figure 1E). In contrast, con-
trol animals, receiving vehicle-treated osmotic minipumps, did not 
exhibit visible tumor growth up to day 190. Thus, EETs accelerate 
the escape from tumor dormancy.
To further examine the extent to which EETs trigger exit from 
dormancy, we serially injected decreasing numbers of LLC tumor 
cells, since implantation below a critical number of tumor cells 
mimics dormancy (23, 27). Systemic administration of 14,15-
EET increased the LLC tumor growth rate when a large number 
(105, 106) of LLC cells was injected; this was achieved without 
accelerating the time to tumor “take-off.” Remarkably, at a lower 
LLC cell number (104), 14,15-EET drastically accelerated the 
time, by 10 days, to tumor take-off, after which the growth rate 
was similar to that of control LLC tumors (Figure 1C). At 103 
injected LLC cells, 14,15-EET–treated mice showed macroscopic 
tumors, albeit with a 32-day delay, growing at the same rate as 
control mice receiving 10 times more (104) cells. By contrast, in 
control mice injected with 103 LLC tumor cells, tumors were not 
visible and remained dormant during the entire 209-day period 
of observation (Figure 1C). Collectively, these data demonstrate 
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that below a critical threshold of tumor cell number, EETs are 
necessary for normal tumor development.
EETs enhance tumor angiogenesis. To determine whether tumor 
angiogenesis contributed to the increase in escape rate as well as pri-
mary tumor growth rate in the genetically altered and 14,15-EET–
treated mice, we analyzed the amount of endothelium in tumors 
by immunohistochemical detection of the EC marker CD31 and by 
flow cytometry. Immunohistochemistry studies showed an increase 
in CD31-positive vessels in B16F10 tumors on day 22 after injec-
tion in Tie2-CYP2C8-Tr, Tie2-CYP2J2-Tr, and sEH-null mice rela-
tive to WT mice (Supplemental Figure 1I). Likewise, flow cytometry 
of dissociated tumor cells revealed a significant increase in CD31-
positive ECs in LLC tumors from Tie2-CYP2J2-Tr mice compared 
with WT mice on day 22 after injection (Supplemental Figure 1J). 
Moreover, tumor-associated angiogenesis increased in 14,15-EET–
treated prostate (PC3M-LN4 and TRAMP) tumors (Supplemental 
Figure 1K). Conversely, CD31-positive vessels decreased in T241 
fibrosarcoma tumors in Tie2-sEH-Tr mice relative to WT mice on 
day 28 after tumor implantation (Supplemental Figure 1L).
To determine whether increased angiogenesis in tumors was 
a consequence of faster tumor growth or a primary response to 
EETs, we performed a corneal tumor angiogenesis assay. This is 
a standard assay in which LLC is implanted into a cornea micro-
pocket and allowed to stimulate neovascularization (28). We 
observed dramatic stimulation of tumor-dependent angiogenesis 
in Tie2-CYP2C8-Tr and sEH-null mice on day 13 after LLC implan-
tation in the cornea (Supplemental Figure 1M). Likewise, systemic 
administration of 14,15-EET enhanced corneal tumor angiogen-
esis when LLC-GFP and B16F10 melanoma were implanted in 
the cornea, as reflected by a 23% increase in CD31-positive ECs 
(Supplemental Figure 1, N and O). These cornea assays allowed us 
to monitor angiogenesis before tumor mass development.
Administration of synthetic EETs or genetic disruption of sEH, 
the EETs’ primary degrading enzyme, increased systemic EET 
levels and mimicked the effects of endothelium-derived EETs in 
the Tie2 promoter–driven CYP transgenic mice. However, we have 
not excluded the possibility that in the latter animals, EETs pro-
duced by monocytes/macrophages could account for the tumor-
promoting effects of EETs, since the Tie2 promoter is also active 
in monocytes/macrophages (29). We therefore depleted macro-
phages with clodronate liposomes (30) in Tie2-CYP2C8-Tr– and 
14,15-EET–treated mice (Supplemental Figure 1P) and observed 
no effect on LLC tumor growth.
EETs stimulate multiorgan metastasis. By manipulating EET levels 
in the tissue, as opposed to CYP expression in tumor cells (as pre-
viously reported; ref. 11), we can now study the direct, systemic 
role of EETs in cancer metastasis. Using a well-established model 
in which resection of a primary tumor reproducibly stimulates 
development of distant metastasis 14–17 days after resection 
(31, 32), we investigated whether EETs promote spontaneous 
metastatic growth (as opposed to inducing metastatic tumors by 
intravenous injection of tumor cells). Autopsies of moribund mice 
10 days after resection of primary LLC revealed a dramatic 
increase in lung weight and in surface lung metastases in both 
Tie2-CYP2C8-Tr and sEH-null mice compared with WT mice (Fig-
ure 2A). In sEH-null mice, the normal lung tissue was completely 
replaced by invasive metastatic lesions (Figure 2A). Tie2-CYP2C8-
Tr and sEH-null mice also exhibited spontaneous liver and kidney 
metastasis (Supplemental Figure 2A). In contrast, there was a 50% 
decrease in the number of lung metastases at day 17 in Tie2-sEH-
Tr mice when compared with WT mice (Figure 2B and Supplemen-
tal Figure 2B). These observations indicate that EETs stimulate 
spontaneous metastasis following resection of a primary tumor 
and, more strikingly, that they are important for the normally 
observed basal metastatic rate in WT mice.
Surprisingly, even without resection of the primary tumor, LLC 
metastases were observed in axillary lymph nodes and lungs of 100% 
of the Tie2-CYP2J2-Tr mice by day 22 after injection (Supplemental 
Figure 2, C and D). In contrast, no gross metastases were observed 
in Tie2-CYP2J2-Tr mice injected with T241 fibrosarcoma.
To determine whether the pro-metastatic effect of endothelium-
derived EETs was limited to the LLC model, we injected B16F10 mel-
anoma cells via the tail vein into Tie2-CYP2C8-Tr mice. In this com-
mon (non-spontaneous) hematogenic metastasis model, B16F10 
cells exclusively colonize the lung and produce pulmonary metastases 
(33). However, in the Tie2-CYP2C8-Tr mice, B16F10 melanoma cells 
produced macroscopic metastasis not only in lung but also in liver 
(Supplemental Figure 2E). This is of interest because liver metastasis 
is commonly only achieved by direct injection of B16F10 melano-
ma cells into the portal or splenic vein (34). In parallel experiments, 
when primary subcutaneous B16F10 tumors were resected to trigger 
distant metastasis (as in the LLC model), there was a large (3-fold) 
increase in axillary lymph node metastasis in both Tie2-CYP2C8-Tr 
and sEH-null mice 17 days after B16F10 melanoma resection (Sup-
plemental Figure 2F). This suggests that macrometastatic lesions 
stimulated by EETs are independent of tumor type. Importantly, 
systemic administration of 14,15-EET via osmotic minipumps in 
WT mice at the time of LLC tumor resection also stimulated a 3-fold 
increase in the number of surface lung metastases compared with 
vehicle-treated controls and led to an induction of liver, kidney, and 
distant lymph node metastasis 12 days after resection of the primary 
LLC tumor (Figure 2C and Supplemental Figure 2G).
Figure 1
EETs stimulate primary tumor growth and escape from tumor dormancy. 
(A) Growth of B16F10 melanoma and T241 fibrosarcoma primary 
tumors in sEH-null, Tie2-CYP2C8-Tr, and WT mice. n = 10–14 mice/
group; *P = 0.042, **P = 0.024, #P = 0.008, §P < 0.001 versus WT; 
unpaired Student’s t test is used throughout. (B) Primary B16F10 mel-
anoma and T241 fibrosarcoma tumor growth is inhibited in Tie2-sEH-
Tr mice on days 22–28. n = 5–6 mice/group; *P = 0.001, **P = 0.006 
versus WT. (C) Systemic administration of 14,15-EET (15 μg/kg/d) via 
osmotic minipump stimulates primary LLC tumor growth. When 1 × 104 
or 1 × 103 LLC cells were injected, 5 of 9 control mice and 9 of 9 control 
mice, respectively, did not exhibit visible tumor growth up to 209 days 
after injection. Images show representative mice on day 29 after injec-
tion with 1 × 104 LLC cells. n = 6–9 mice/group; *P ≤ 0.02, **P ≤ 0.001, 
#P ≤ 0.006 versus WT. The experiment was performed 3 times with 
similar results. Rulers show centimeters. (D) 14,15-EET (15 μg/kg/d) 
stimulates tumor growth in a genetically engineered model of cancer 
(TRAMP). Ruler shows centimeters. At 90 days of treatment, H&E-
stained section of prostate of control TRAMP mice reveals prostatic 
intraepithelial neoplasia (PIN) surrounded by tumor cells, while H&E-
stained section of prostate of TRAMP mice treated with 14,15-EET 
shows glandular parenchyma surrounded by tumor cells. n = 6 mice/
group; *P = 0.002 versus control. Scale bars: 100 μm. (E) 14,15-EET 
accelerates escape in a tumor dormancy model of human liposarcoma 
cells (clone 4). After treatment with 14,15-EET for 100 days, large pal-
pable liposarcoma tumors are visible. No tumor is visible in the control 
mice. Ruler shows centimeters. H&E-stained section of tumors of mice 
treated with 14,15-EET reveal sheets of lipoblasts. n = 5–6 mice/group; 
*P = 0.008 versus control. Scale bar: 100 μm.
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To confirm that the atypical lymph node lesions indeed repre-
sented metastatic tumors derived from the primary LLC tumor 
cells, we repeated the metastasis experiments using GFP-labeled 
LLC tumors in mice administered 14,15-EET systemically. Resec-
tion of the primary GFP-LLC tumor again stimulated pronounced 
axillary and inguinal lymph node masses that contained abundant 
GFP-positive LLC tumor cells (Figure 2C), thus excluding the pos-
sibility that lymph node masses were due to reactive lymphade-
nopathy. Accordingly, in our other metastasis model, systemic 
administration of 14,15-EET to mice injected with GFP-labeled 
B16F10 melanoma cells via tail vein also induced multiorgan 
metastasis of the injected cells, as indicated by GFP-labeled tumor 
cells in the lung, liver, and kidney (Figure 2D). Although 14,15-EET 
induced melanocytic metastases in the lung, the metastases in the 
liver and kidney were amelanotic (Figure 2D and Supplemental 
Figure 2H), consistent with previous studies indicating that the 
organ microenvironment influences pigmentation of metastatic 
murine melanoma (35). Liver metastasis was also achieved by sys-
temic administration of 14,15-EET for 28 days to mice carrying the 
orthotopic human prostate cancer (PC3M-LN4), whereas control 
vehicle-treated mice did not exhibit any liver metastasis (Figure 2E). 
Such metastasis is unexpected in this tumor model, which typically 
develops paraaortic lymph node metastases, which indeed was con-
sistently observed in the 14,15-EET–treated but only occasionally 
in the control-treated TRAMP animals (data not shown).
Pharmacological control of EETs in cancer. To confirm the observed 
effects of exogenous 14,15-EET and to establish the clinical rel-
evance of pharmacological EET modulation, we characterized 
the effect of EET-modifying drugs in primary tumor and metas-
tasis models. First, we studied compounds that increase EETs by 
inhibiting sEH. Notably, sEH inhibitors similar to tAUCB, as well 
as the structurally dissimilar TUPS, are currently being tested in 
clinical trials for treatment of hypertension (4, 36). Treatment of 
mice with tAUCB, which elevated plasma EET levels up to 3-fold 
(Supplemental Figure 3A), accelerated primary LLC-GFP tumor 
growth (Figure 3A). LC/MS/MS analysis of LLC-GFP tumors 
treated with tAUCB showed no change in EET levels in the tumor 
tissue (Supplemental Figure 3B). Immunohistochemical analysis 
of tAUCB-treated LLC-GFP tumors revealed an increase in the 
number of tumor cells expressing VEGF and a marked increase 
in microvessels, as stained by the EC marker MECA-32 (Figure 3B 
and Supplemental Figure 3C). Systemic administration of either 
tAUCB or TUPS dramatically stimulated lung, liver, and axillary 
lymph node metastasis in two different murine tumor models 
(LLC and B16F10 primary tumor resection) (Figure 3C and Sup-
plemental Figure 3D). The sEH inhibitors (TUPS and tAUCB) also 
promoted lymph node metastasis after B16F10 tumor resection to 
greater than 10%–20% of body weight (Figure 3C). The use of GFP-
labeled tumor cells and immunohistochemistry again confirmed 
that this lymph node enlargement was caused by metastatic tumor 
cells (Supplemental Figure 3, E and F).
Conversely, mice with established LLC tumors treated with 
the putative EET receptor antagonist 14,15-EEZE demonstrated 
reduced primary LLC growth, prolonged survival in the LLC resec-
tion metastasis model, and reduced plasma VEGF levels (Figure 
3D). While the receptor(s) for EETs have not yet been identified 
(4), EET antagonists are the most specific reagents available for 
pharmacologic suppression of EET activity (37, 38) and have been 
used to antagonize the biological effects of EETs in other disease 
models (39–43). To determine whether an EET antagonist could 
prevent EET-induced metastasis, we co-administered the EET 
antagonist 14,15-EEZE-mSI with 14,15-EET following LLC pri-
mary tumor resection. The EET antagonist drastically reduced 
lung metastasis and prevented the macroscopic liver and lymph 
node metastasis typically induced by 14,15-EET (Figure 3E) with-
out apparent toxic effects. In addition, systemic administration of 
the EET antagonist 14,15-EEZE inhibited lung and lymph node 
metastases in Tie2-CYP2C8-Tr and sEH-null mice (Supplemental 
Figure 3G). Vessel density decreased in B16F10-GFP tumors treat-
ed with 14,15-EEZE (Supplemental Figure 3H). Thus, pharmaco-
logical modulation of EET levels recapitulates the results obtained 
in genetically altered mice with respect to both stimulation and 
suppression of primary tumor and metastatic growth.
EETs require VEGF for tumor progression. Since the receptor(s) for 
EETs are unknown (4), it is difficult to elucidate the cellular and 
molecular targets of EETs in promoting cancer. We examined pos-
sible cellular processes that might mediate the effects of EETs on 
tumor growth and metastasis. Increased metastasis in part results 
from increased EC migration, a critical component of the metastatic 
cascade (44, 45). ECs isolated from the aortas of Tie2-sEH-Tr mice, 
which have endothelium-specific staining of sEH (Supplemental 
Figure 4A), exhibited decreased migration on collagen substrates 
when compared with aortic ECs from WT mice (Figure 4A). In con-
trast, ECs from Tie2-CYP2J2-Tr and Tie2-CYP2C8-Tr mice exhib-
ited increased migration relative to WT ECs (Figure 4A). tAUCB and 
TUPS had no significant effects on basal endothelial migration but 
increased VEGF-mediated endothelial migration 2- to 3-fold (Figure 
4A). In contrast, the putative EET receptor antagonist 14,15-EEZE 
inhibited EC migration in a dose-dependent fashion but had no sig-
nificant effect on migration of LLC tumor cells (Figure 4B).
Figure 2
EETs trigger spontaneous and multiorgan metastasis. (A) Spontane-
ous LLC metastasis is increased in Tie2-CYP2C8-Tr and sEH-null mice 
relative to WT 10 days after primary tumor removal (LLC resection). 
Images show representative lung metastasis in transgenic and WT 
mice. n = 5 mice/group; *P = 0.011, **P = 0.004, ***P ≤ 0.001 versus 
WT. The experiment was performed 3 times, with similar results. Scale 
bars: 1 cm. (B) Spontaneous LLC metastasis is decreased in Tie2-
sEH-Tr relative to WT 17 days after primary tumor removal. n = 6 mice/
group; *P = 0.001, **P = 0.002. (C) Systemic administration of 14,15-
EET (15 μg/kg/d) via osmotic minipump increases spontaneous LLC 
lung metastasis and distant axillary and inguinal lymph node metastasis 
12 days after LLC resection. Dashed circles indicates metastatic and 
normal lung; arrows show inguinal lymph node metastasis (white arrow, 
14,15-EET; black arrow, control); scale bars: 1 cm. GFP-labeled LLC 
tumor cells (green) demonstrate bilateral axillary and inguinal lymph 
node metastasis in mice treated with 14,15-EET 17 days after LLC-
GFP tumor resection; scale bars: 500 μm (for GFP staining). n = 10 
mice/group; *P = 0.001, **P ≤ 0.001. (D) 14,15-EET (15 μg/kg/d) reduc-
es survival and stimulates multiorgan lung, liver, and kidney metastasis 
of B16F10-GFP melanoma cells injected intravenously. Dashed circles 
indicate (top to bottom) representative lung, liver, and kidney metas-
tasis 19 days after injection; scale bar: 1 cm. GFP-labeled melanoma 
tumor cells (green) confirm lung, liver, and kidney metastasis in mice 
treated with 14,15-EET; scale bar: 500 μm (for GFP staining). n = 7–9 
mice/group; *P = 0.021. (E) 14,15-EET (15 μg/kg/d) stimulates liver 
metastasis in an orthotopic human prostate cancer (PC3M-LN4) model. 
H&E-stained section of liver metastasis of mice treated with 14,15-EET; 
arrows indicate nodules of tumor within hepatic parenchyma; scale 
bar: 100 μm. Black circles indicate representative orthotopic prostate 
tumors; scale bars: 1 cm. n = 5–6 mice/group.
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Both Tie2-CYP2C8-Tr and sEH-null mice exhibited a significant 
increase in plasma levels of VEGF when compared with WT mice 
(Figure 4C). 14,15-EET upregulated the VEGF receptor VEGFR2 
but not VEGFR1 in LLC tumors in comparison to size-matched 
control tumors (Figure 4C), suggesting the typical VEGF-VEGFR2 
interaction reported for ECs (46). Immunohistochemistry of 
14,15-EET–treated LLC tumors showed mild to moderate VEGFR2 
expression in ECs, leukocytes (including macrophages), and a 
few tumor cells (Supplemental Figure 4, B and C). To determine 
whether VEGF-stimulated angiogenesis plays a functional role in 
EET-mediated tumor growth, we depleted VEGF by expressing a 
soluble form of VEGF receptor 1 (sFlt) using an adenoviral deliv-
ery system (47). In WT mice, which have low systemic VEGF lev-
els, tumor growth was approximately half that in the high-EET 
mice (Figure 4D), and VEGF depletion had no significant effect 
on primary B16F10 melanoma growth (Figure 4D). In contrast, 
in Tie2-CYP2J2-Tr and sEH-null mice, where EET and VEGF lev-
els were higher than in WT mice, VEGF depletion suppressed the 
accelerated B16F10 melanoma tumor growth by up to 80% at day 
19 after tumor injection (Figure 4D). In fact, tAUCB was unable to 
promote tumor growth and metastasis in mice depleted of VEGF 
by Ad-sFlt (Figure 4E and Supplemental Figure 4D). Thus, EETs 
require VEGF for tumor progression.
Interestingly, B16F10 tumors in mice expressing sFlt eventually 
escaped the VEGF depletion, suggesting that changes in other regu-
lators of tumor angiogenesis, such as thrombospondin-1 (TSP1), 
which is an angiogenesis inhibitor (48), may also play a role. Indeed, 
plasma from tumor-bearing Tie2-CYP2C8-Tr, Tie2-CYP2J2-Tr, and 
sEH-null mice exhibited a pronounced reduction in the levels of 
TSP1 at day 13 after injection when compared with WT mice (Fig-
ure 4F), suggesting that this effect may contribute to the tumor-
promoting activity of EETs and may help to overcome the neutral-
ization of VEGF. Stromal TSP1 expression was markedly decreased 
in three different tumors (LLC, B16F10 melanoma, and T241 fibro-
sarcoma) in Tie2-CYP2C8-Tr and sEH-null mice when compared 
with WT mice (Supplemental Figure 4E). In addition, 14,15-EET 
specifically decreased TSP1 production in fibroblasts but had no 
effect on TSP1 production in tumor and ECs in vitro (Supplemen-
tal Figure 4F). To evaluate the potential role of TSP1 suppression as 
a mediator of EET-induced tumor angiogenesis, we treated TSP1-
deficient (TSP1-null) mice with the EET antagonist 14,15-EEZE 
and found that tumor suppression by the EET antagonist was 
significantly diminished, by 62%, in WT mice (Figure 3D) to 24% 
in TSP1-null mice (Figure 4G). Thus, regulation of TSP1 by EET 
antagonists may contribute to their tumor-suppressive activity.
Given the elevated plasma VEGF levels in Tie2-CYP2J2-Tr and 
sEH-null mice, we next asked whether EETs had an effect on VEGF 
production. We found that 14,15-EET increased VEGF produc-
tion by tumor cells and ECs in vitro but had no effect on VEGF 
production in fibroblasts (Supplemental Figure 4G). VEGF can 
be produced by tumor stromal cells (49). To identify the source of 
VEGF, we analyzed LLC tumors in VEGF-LacZ-Tr mice, in which 
the LacZ reporter was introduced into the VEGF locus (50). Inter-
estingly, the endothelium and other stromal cells of LLC tumors 
grown in VEGF-LacZ-Tr mice systemically treated with 14,15-EET 
stained positively for the LacZ product β-galactosidase, whereas 
this marker for VEGF production was absent in the stroma of size-
matched control tumors of nontreated mice (Figure 5A).
Source of EETs in advanced tumors. If EETs stimulate tumor angio-
genesis, what causes EET production to rise during progressive 
tumor growth? In humans, expression of sEH (which metabo-
lizes EETs) is downregulated in hepatic and renal cancer (51). To 
determine whether the loss of the enzyme sEH indeed occurs in 
the endothelium and if respective changes in CYP epoxygenase and 
sEH expression contribute to tumor progression via increase in 
EETs, we analyzed isolated tumor ECs and normal “quiescent” ECs 
(52) and measured expression of sEH, CYP2C, and CYP2J proteins. 
While CYP2C and CYP2J levels were similar in the two populations 
of ECs, we observed a significant decrease in sEH in tumor ECs 
in comparison to normal ECs (Figure 5B and Supplemental Fig-
ure 4G). In contrast, all murine tumor cell lines that we examined 
expressed sEH, CYP2C, and CYP2J in vitro, except for LLC, which 
appeared to be CYP2J-negative (Supplemental Figure 4H). By con-
trast, examination of LLC tumor lysates revealed that expression 
of sEH, but not CYPs, decreased with tumor progression (Figure 
5B). Similarly, sEH expression was suppressed in liver metastasis of 
B16F10 melanoma tumors compared with adjacent normal liver 
tissue (Figure 5B). Collectively, these findings indicate that tumor 
growth and progression are associated with decreased sEH expres-
sion, most notably in the tumor endothelium, suggesting that 
downregulation of sEH may account for the increased EETs and 
subsequent stimulation of angiogenesis in progressing tumors.
Endothelial EETs act at secondary sites in metastasis. High endothelial 
EET levels induced a dramatic increase in number, size, and spread 
of distant metastases. To determine whether the systemic modula-
tion of EET levels facilitates cancer cell dissemination at the pri-
mary tumor site (by promoting extravasation and migration) or at 
the metastatic site (by promoting homing, colonization, dormancy 
escape, and survival), we utilized a parabiosis model with a shared 
circulatory system (53, 54), with a tumor-bearing (donor) mouse 
with high EET levels (Tie2-CYP2C8-Tr or sEH-null) conjoined 
to a non-tumor-bearing (recipient) mouse with normal or low 
endothelial EET levels (WT or Tie2-sEH-Tr, respectively). Other 
configurations served as controls. The sharing of humoral factors 
Figure 3
Pharmacological modulation of EET levels controls primary tumor 
growth and metastasis. (A) Systemic administration of an sEH inhibi-
tor (tAUCB) stimulates primary LLC-GFP tumor growth. Images show 
representative tumors after 13 days of treatment. n = 6 mice/group; 
*P = 0.007. Scale bar: 1 cm. (B) Immunofluorescence double staining 
for VEGF and GFP (tumor cells) shows increased tumor cell expres-
sion of VEGF in LLC-GFP tumor cells from tAUCB- versus vehicle-
treated mice. Green, GFP-stained tumor cells; red, VEGF-containing 
cells. Colocalization of red and green fluorescence (yellow) indicates 
tumor cells expressing VEGF (arrows). tAUCB-treated tumors have 
an increase in MECA-32–positive ECs (green). Scale bars: 20 μm. 
(C) Systemic administration of tAUCB and TUPS (10 mg/kg/d each) 
increases spontaneous B16F10 axillary lymph node metastasis 21 
days after B16F10 resection. Representative axillary lymph nodes 
after 21 days of treatment are shown. Scale bars: 1 cm. n = 6 mice/
group; *P = 0.029 versus control. (D) The EET antagonist 14,15-EEZE 
(0.21 mg/mouse) inhibits primary LLC growth (left panel), prolongs 
survival (middle panel), and reduces plasma VEGF levels (right panel) 
in a spontaneous LLC lung metastasis model. n = 5 mice/group; 
*P = 0.017, **P = 0.035, ***P = 0.044. (E) The EET antagonist 14,15-
EEZE-mSI (0.21 mg/mouse) inhibits 14,15-EET–induced (15 μg/kg/d) 
spontaneous LLC metastasis. The stable EET metabolite 14,15-DHET 
(15 μg/kg/d) does not stimulate metastasis. Representative photo-
graphs on day 12 after LLC resection are shown. Scale bars: 1 cm. 
n = 5 mice/group; *P < 0.001, **P = 0.003 versus 14,15-EET.
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Figure 4
Pro-tumorigenic activity of endothelium-derived EETs is mediated by VEGF induction and loss of TSP1. (A) EC migration is decreased in 
Tie2-sEH-Tr mice (left panel) but increased in Tie2-CYP2J2-Tr and Tie2-CYP2C8-Tr relative to WT mice (middle). tAUCB and TUPS stimulate 
VEGF-mediated endothelial migration (right). n = 3–4/group; *P = 0.0139, **P = 0.029, and ***P < 0.001 versus WT; †P < 0.05 versus VEGF 
alone. (B) 14,15-EEZE inhibits VEGF-induced EC (left panel) but not tumor cell (LLC) migration (right). n = 3–4/group; *P = 0.038, **P = 0.012, 
***P < 0.001 versus control. (C) VEGF ELISA of plasma of Tie2-CYP2C8-Tr and sEH-null mice 17 days after B16F10 resection shows an 
increase in VEGF levels. n = 5/group (left panel). Systemic administration of 14,15-EET regulates Vegfr2 mRNA levels in primary LLC tumors 
in mice compared with size matched control tumors, but has no effect on Vegfr1 mRNA levels (right). n = 5/group. *P < 0.05 versus WT; 
**P = 0.0095 versus control. (D) VEGF depletion with Ad-sFlt suppresses B16F10 tumor growth in Tie2-CYP2J2-Tr and sEH-null but not in WT 
mice. Plasma levels of sFlt1 on day 10 were 35,999 ± 10,225 pg/ml (Tie2-CYP2J2-Tr) and 36,680 ± 1,308 pg/ml (sEH-null). n = 5 mice/group; 
*P = 0.016, **P = 0.023. (E) tAUCB does not promote spontaneous LLC metastasis in mice depleted of VEGF with Ad-sFlt (tAUCB + Ad-sFlt). 
n = 5 mice/group; *P = 0.004, **P = 0.002 versus tAUCB + Ad-null. (F) The angiogenesis inhibitor TSP1 is downregulated in plasma of Tie2-
CYP2C8-Tr, sEH-null, and Tie2-CYP2J2-Tr relative to WT mice on day 13 after LLC injection. rTSP1, recombinant TSP1. (G) 14,15-EEZE 
(0.21 mg/mouse) does not significantly inhibit primary LLC tumor growth in TSP1 null mice. n = 5 mice/group.
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in the parabiotic circulation was confirmed using Evans blue dye 
as a tracer (Supplemental Figure 5, A and B). Results of the experi-
ments are summarized in Tables 1 and 2 and Supplemental Figure 
5C. In the control configuration — in which two “high-EET” mice 
were parabiosed but only one carried the primary tumor — liver, 
lung, and lymph node metastases occurred in both parabionts, 
demonstrating that parabiosis itself did not interfere with EET-
promoted metastasis (Tables 1 and 2, cases b, c, and i). Moreover, 
the genotype of the tumor-bearing donor mouse determined the 
growth of the primary tumor (in the donor mouse), regardless of 
the genotype of the recipient mouse. Specifically, sEH-null (high-
EET) recipients could not rescue the tumor phenotype of Tie2-
sEH-Tr (low-EET) donors (Table 1, case f). It is possible that the 
high EET levels in the plasma of sEH-null mice, which are shared 
by both partners, were not sufficient to rescue tumor growth in 
the Tie2-sEH-Tr mice, where the sEH enzyme acts as a local sink 
to keep EET levels in the endothelium low. In the key configura-
tion, a low-EET recipient attached to a high-EET donor failed to 
produce metastasis (Table 2, cases j and k), demonstrating that 
a high-EET-producing endothelium is critical at the metastatic 
site for lung, liver, and lymph node metastases to occur. Impor-
tantly, adoptive transfer of whole blood from low-EET recipient 
parabionts (Tie2-sEH-Tr), which exhibited no metastasis, caused 
metastatic disease when inoculated into nonparabiotic high-EET 
(Tie2-CYP2C8-Tr) mice, confirming that the low-EET parabiont 
had circulating tumor cells. Indeed, 28 days after injection, 100% 
of the WT recipients of such blood transfer survived, while 50% of 
the Tie2-CYP2C8-Tr blood transfer recipients died of metastasis 
(Supplemental Figure 5D). Immunofluorescence staining of histo-
logical sections of tumors removed from the high-EET parabionts 
showed increased tumor EC proliferation and increased VEGF 
production (Supplemental Figure 5E). Together, these findings 
document the requirement for high EET levels in the endothelium 
of the metastatic site in order for metastasis to occur.
Discussion
We demonstrate that exogenous administration of EETs in vivo 
promote tumor growth, as well as dramatically enhancing meta-
static spread in several tumor models known to metastasize poorly. 
Specifically, in Tie2-CYP transgenic mice, which are engineered to 
raise endothelial EET levels, tumors that rarely metastasize exhibit 
extensive metastatic spread into a range of organs, including lung, 
axillary lymph nodes, liver, and kidney. Exogenous administra-
tion of EETs induce multiorgan metastasis and tumor dormancy 
escape in a variety of transplantable and genetically engineered 
cancer models to a high degree, providing what we believe to be 
the first in vivo demonstration that pharmacological modulation 
of these lipid autacoids affects tumor growth.
EETs promote metastasis by triggering secretion of VEGF by 
the endothelium, which we show to be critical for EETs’ cancer-
stimulating activity. We also demonstrate that stimulation of 
metastasis by EETs is due to their action at the secondary (metas-
tasis) site and not due to their effect on the cells of the primary 
tumor. We arrived at this insight by dissecting the two steps of 
metastasis using a series of parabiosis experiments in which mice 
transgenically modified to produce either low or high levels of 
EET in the endothelium were surgically cojoined. Using parabio-
sis, we have delineated and identified the distinct roles of stromal 
Figure 5
Pro-tumorigenic activity of EETs is mediated by VEGF production in the tumor stroma and loss of sEH. (A) LLC tumors in VEGF-LacZ-Tr mice 
treated with 14,15-EET (15 μg/kg/d) show β-galactosidase staining (marker of VEGF production) in tumor endothelium and stromal fibroblasts 
(arrows). Scale bars: 20 μm. (B) Expression of sEH, but not CYP2J and CYP2C, is downregulated in tumor (TEC) versus normal (NEC) ECs 
(two left panels). Control tissue: mouse liver. Expression of sEH, but not CYP2J and CYP2C, is downregulated in tumor lysates from larger LLC 
tumors (>5 cm3) versus smaller LLC tumors (<1 cm3) (third panel). sEH expression (brown staining) is also downregulated in B16F10 melanoma 
liver metastasis compared with normal adjacent liver (far right panel). Scale bar: 100 μm.
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EET levels in promoting or inhibiting growth of the primary 
tumor and at the point of metastasis.
Although we show that the endothelium, acting as a source of 
local EETs, is a critical regulator of primary tumor growth and 
metastasis, our studies with exogenously administrated 14,15-EET 
indicate that high levels of systemic EETs can also stimulate tumor 
growth and metastasis. The levels of EETs after adenoviral CYP 
expression increase approximately 3- to 5-fold in vitro (11). Treat-
ment with 14,15-EET via osmotic minipump in our studies yielded a 
plasma steady-state EET concentration of approximately 3.0 ng/ml, 
twice that observed in sEH null mice (~1.5 ng/ml), which have high 
levels of systemic EETs, and 15- to 30-fold higher than that in Tie2-
CYP2J2-Tr and Tie2-CYP2C8-Tr mice (100–200 pg/ml). This may 
explain why systemic exogenous 14,15-EET was able to stimulate 
tumor growth, whereas in the parabiosis studies, the high-EET part-
ner (e.g., sEH-null mouse) failed to rescue tumor growth in the low-
EET partner. Plasma EET levels were likely diluted in the parabiosed 
low-EET partner to levels that approximate those in WT mice.
Our work demonstrates a number of important findings on lipid 
autacoids and in particular EETs in tumor biology. We establish 
a connection between the disparate fields of lipid autacoids and 
tumor biology. By manipulating EET levels in vivo, as opposed to 
CYP levels or activity (11), we demonstrate the dramatic metastatic 
potential of EETs on low-metastasizing tumors, thereby opening 
an avenue for metastasis research, which has suffered from the 
scarcity of spontaneous metastasis models. EETs in the endothe-
lium may also be a key paracrine mediator of the tumor-promot-
ing role of the stroma, revealing a trophic function for the endo-
thelium in promoting tumor growth 
in addition to its role in providing 
circulation. Inflammatory cells such 
as macrophages may also contribute 
to EET-mediated tumor growth. We 
also demonstrate that sEH inhibitors, 
which elevate endogenous EET levels, 
promote primary tumor growth and 
metastasis. Our findings are of poten-
tial clinical relevance because drugs 
that raise EET levels are now in clinical 
trials for the treatment of hypertension 
and are being considered for long-term 
use in other medical conditions (4, 5). 
Our finding that sEH inhibitors pro-
mote tumor growth, notably explosive 
metastatic growth from presumably 
dormant disseminated tumor cells, 
raises significant concerns about the 
use of sEH inhibitors, especially their 
chronic use, which may adversely affect 
cancer patients. Dormant tumors have 
been identified at autopsy in normal 
adults who died of trauma and with-
out prior history of clinical evidence of 
cancer, including 39% for in situ breast 
carcinoma, 46% for in situ prostate 
cancer, and 36% for thyroid carcinoma 
in people aged 50–70 (55, 56). The fac-
tors that regulate tumor dormancy and 
escape from it are poorly understood 
(57). The escape is critically dependent 
on the induction of angiogenesis (22, 25, 26, 44). Our data suggest 
that the increase in EET levels, due to downregulation of sEH, may 
support the angiogenic switch in part by an increase in VEGFR2 
and loss of thrombospondin.
We also demonstrate the ability of EET antagonists to inhibit 
tumor growth and metastasis. These results could pave the way for 
a new strategy for the prevention and treatment of metastatic dis-
ease — i.e., inhibition of EET bioactivity. Specific EET antagonists, 
inhibitors of endothelial CYP epoxygenases, or the overexpression 
of EET-metabolizing enzymes may represent new strategies for the 
treatment of angiogenic diseases, including cancer. Manipulation 
of the EET system is thus a double-edged sword, and further stud-
ies are needed to carefully evaluate the benefits as well as the risks 
in the clinical modulation of these lipid mediators.
Methods
Generation of Tie2-CYP2J2, Tie2-CYP2C8, and Tie2-sEH transgenic mice. Trans-
genic mice expressing human CYP2J2, CYP2C8, or sEH in ECs were 
developed on a C57BL/6 background. The human CYP2J2 (GenBank 
NM_000775), CYP2C8 (NM_000770), and sEH (NM001979) cDNA 
sequences were subcloned downstream of the murine Tie2 promoter and 
upstream of the Tie2 full enhancer sequences (provided by Thomas N. Sato, 
University of Texas Southwestern Medical Center) to drive endothelial 
expression, as described previously (15, 18, 58). Linearized constructs were 
excised from the vector backbone, agarose gel purified, microinjected into 
pronuclei of single-cell C57BL/6J mouse embryos, and implanted into 
pseudopregnant mice. Hemizygous founder pups were identified via PCR 
genotyping of genomic DNA. Breeding involved crossing hemizygous Tie2-
Table 1
Parabiosis donor/recipient constellations on primary tumor growth (LLC)
Case	 Parabiotic	donor	 Recipient	(site)	 Primary	tumor	volume	
	 	(site	of	primary	tumor)	 	 (mm3)
a WT WT 1,565 ± 170
b sEH-null → EET high sEH-null → EET high 6,869 ± 311A
c Tie2-CYP2C8-Tr → EET high Tie2-CYP2C8-Tr → EET high 5,632 ± 1,004A
d sEH-null → EET high Tie2-sEH-Tr → EET low 6,123 ± 505A
e Tie2-CYP2C8-Tr → EET high WT → EET low 5,046 ± 526A
f Tie2-sEH-Tr → EET low sEH-null → EET high 1,333 ± 183
g Tie2-sEH-Tr → EET very low Tie2-sEH-Tr → EET very low 1,031 ± 186
Parabiosis shows that EET-stimulated tumor growth depends on genotype of tumor-bearing parabiont 
(donor). Parabiosis was performed for 4–5 pairs per configuration and mean tumor volume ± SEM deter-
mined. AP < 0.05 versus cases a, f, and g.
Table 2
Parabiosis donor/recipient constellations on spontaneous LLC metastasis
Case	 Parabiotic	donor		 Recipient	(site)	 No.	surface	lung		
	 (site	of	primary	tumor)	 	 metastasis	in	recipient
h WT WT No mets
i Tie2-CYP2C8-Tr → EET high Tie2-CYP2C8-Tr → EET high 27 ± 4; 3 of 4, liver mets;  
   3 of 4, LN metsA
j Tie2-CYP2C8-Tr → EET high WT → EET low No mets
k Tie2-CYP2C8-Tr → EET high Tie2-sEH → EET very low No mets
Parabiosis shows that metastasis requires EET-producing endothelium at the metastatic site in the recipi-
ent parabiont. Parabiosis was performed for 4–5 pairs per configuration and mean number of metastases 
(mets) ± SEM determined. AP < 0.05 versus cases h, j, and k.
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CYP2J2-Tr, Tie2-CYP2C8-Tr, and Tie2-sEH-Tr founder mice with C57BL/6 
WT mice in order to obtain heterozygous Tr (+/–) and WT littermates (–/–) 
at an approximate ratio of 1:1. All studies used adult F2–F7 Tie2-CYP2J2-Tr, 
Tie2-CYP2C8-Tr, Tie2-sEH-Tr, and WT littermates as controls, were com-
pleted in accordance with the NIH Guide for the Care and Use of Laboratory 
Animals, and were approved by the Animal Care and Use Committee of 
NIEHS and Children’s Hospital, Boston.
Materials. LLC, LLC-GFP, B16F10 melanoma, and T241 fibrosarcoma 
cells were cultured as described previously (32). 14,15-EET and 14,15-DHET 
were obtained from Cayman Chemical. 14,15-EET, 14,15-DHET, or vehicle 
was administered intraperitoneally via osmotic minipump (Alzet) at a dose 
of 15 μg/kg/d. The sEH inhibitors (tAUCB and TUPS) were administered 
orally by gavage in an aqueous solution of 10% DMSO in 0.5% methylcellu-
lose, whereas control mice received vehicle. After the ethanol was evaporated 
under a stream of nitrogen gas, EET antagonists 14,15-EEZE and 14,15-
EEZE-mSI were administered orally by gavage in an aqueous solution in 
0.5% methylcellulose, while control mice received vehicle.
Tumor xenograft and metastasis studies. All animal studies were reviewed and 
approved by the Animal Care and Use Committee of Children’s Hospital, 
Boston. Six-month-old male transgenic and WT mice on a pure C57BL/6 
background were used. LLC, B16F10 melanoma, and T241 fibrosarcoma 
tumor cells were injected as described previously (28). For metastasis 
studies, LLC or B16F10 melanoma tumors were resected 14–21 days after 
implantation as described (31). B16F10 melanoma cells were injected 
intravenously as described (28). For pharmacological modulation of EETs, 
tumors in male, 6-week-old C57BL/6J mice (The Jackson Laboratory) were 
allowed to reach 100 mm3 before sEH inhibitors (tAUCB and TUPS), EET 
antagonists (14,15-EEZE and 14,15-EEZE-mSI), or vehicle were admin-
istered by daily gavage for 11–21 days. For metastasis studies, LLC or 
B16F10 melanoma tumors were resected 17 days after injection. After LLC 
or B16F10 melanoma resection, mice were treated with sEH inhibitors 
(tAUCB and TUPS), EET antagonists (14,15-EEZE and 14,15-EEZE-mSI), 
or vehicle. In VEGF-LacZ-Tr mice, 14,15-EET (Cayman Chemical, 30% in 
EtOH) or vehicle was administered intraperitoneally via osmotic mini-
pump (Alzet) at a dose of 15 μg/kg/d on the day of LLC tumor injection. In 
TRAMP mice (129S background, The Jackson Laboratory), 14,15-EET or 
vehicle was administered intraperitoneally via osmotic minipump (Alzet) 
at a dose of 15 μg/kg/d when mice were 4–6 weeks of age, and osmotic 
minipumps were changed once a month for 4 months. For LLC, tumor 
cells were injected at 1 × 106, 1 × 105, 1 × 104, and 1 × 103 cells, and 14,15-
EET or vehicle osmotic pumps were implanted on the day of injection and 
changed every 2 weeks for 28 days. For orthotopic human prostate can-
cer, 2 × 105 PC3M-LC4 cells were injected in 6-week-old male SCID mice 
(MGH) as described previously (20). For human liposarcoma, clone 4 (non-
angiogenic) cells were injected into 6-week-old male SCID mice (MGH) as 
described previously (25) at 10-fold fewer cells than normally injected. For 
PC3M-LN4, osmotic pumps were implanted on the day of injection and 
changed once at two weeks. For liposarcoma clone 4, osmotic pumps were 
implanted on the day of injection and changed once a month for 3 months. 
For GFP-labeled metastasis studies, LLC-GFP or B16F10-GFP was injected 
subcutaneously into 6-week-old male C57BL/6 mice (The Jackson Labora-
tory) at 1 × 106 cells; tumors were resected once they had reached a size of 
2–4 cm3, and osmotic pumps were implanted on the day of resection and 
changed every two weeks. B16F10-GFP was injected in 6-week-old male 
C57BL/6 (The Jackson Laboratory) intravenously at 2.5 × 105 cells, and 
osmotic pumps were changed every 2 weeks.
Parabiosis. Parabiosis was performed and cross-circulation assessed in a 
subset of animals (n = 3 couples) from each study condition as we previously 
described (54). Organs were harvested 3 hours after injection from each ani-
mal for densitometric analysis to verify dye cross-circulation. For tumor and 
metastasis experiments, LLC tumors were resected 4 weeks after injection. 
For adoptive transfer of blood cells, whole blood was taken from the low-
EET recipient parabiont (Tie2-sEH-Tr) and inoculated retro-orbitally (300 
μl) into non-parabiosis high-EET (Tie2-CYP2C8-Tr) and WT mice. For in 
vivo VEGF depletion, Ad-null and Ad-sFlt were administered systemically 
5 days prior to tumor injection and 2 days after tumor injection: Ad-null, 
1 × 109 U; Ad-sFlt, 1 × 109 U. Plasma sFlt levels were measured by ELISA (R&D 
Systems). Quantification of ECs in the primary LLC tumors was performed 
by FACS following enzymatic digestion as described previously (59).
Flow cytometry analysis. For flow cytometry on corneal tumors, whole 
eyes were removed and single-cell suspensions were prepared by enzymatic 
digestions as described previously (59) and incubated with Liberase. The 
percentage of ECs (CD-31-positive and CD45-negative) was determined 
using PE- and APC-conjugated antibodies (Roche). Digested tissue was fil-
tered through a cell strainer and resuspended in FACS Buffer (PBS, 1% BSA, 
5 mM EDTA/0.05% sodium azide). Flow cytometry was performed using 
FACSCalibur and CellQuest software (BD Biosciences). For LLC-GFP, only 
the population of FL1hi cells (GFP-expressing cells) was collected for analy-
sis. Data were collected using CellQuest software (BD Biosciences) and ana-
lyzed using WinMDI 2.8 software (http://facs.scripps.edu/software.html).
For macrophage depletion studies, macrophages were depleted by clo-
dronate liposomes, and depletion was confirmed by flow cytometry as 
described previously (30).
Western blot analysis. We isolated tumor ECs and normal quiescent ECs as 
we previously described (52) and analyzed ECs, murine prostate tumor cells 
(TRAMP C1), and LLC tumor lysates from small (LLC <1 cm3) and larger 
(LLC >5 cm3), rapidly growing tumors for the expression of sEH, CYP2C, 
and CYP2J by Western blotting. Western blot analysis of tumors was per-
formed as we described previously (32). Plasma from LLC tumor–bearing-
mice was purified using a heparin bead affinity technique and analyzed for 
TSP1 as we described (60).
Immunohistochemistry. Tumor samples were processed and immuno-
histochemical stainings performed as described previously (28). PECAM 
(CD31), MECA-32, and CD45 staining was performed as described (60). 
Sections were microwaved in 10 mM sodium citrate (pH 6.0) for Ki67, 
TSP1 (Lab Vision), and VEGF (Lab Vision). Sections were microwaved in 
EDTA (Zymed, Invitrogen) for VEGFR2 (Cell Signaling Technology). For 
sEH (Santa Cruz Biotechnology Inc.), sections were heated in citrate in a 
pressure cooker at 120°C for 3 minutes. Ki67 (Vector Laboratories), sEH 
(Santa Cruz Biotechnology Inc.), GFP (Abcam), and VEGF (Thermo Sci-
entific) were incubated at 4°C overnight. Histological sections of tumors 
were analyzed for vessel density as described (32). β-Galactosidase staining 
was performed as described (50). Immunostaining and localization of GFP-
labeled tumors were analyzed using a confocal Leica SP2 microscope.
Angiogenesis assay. All animal studies were reviewed and approved by the 
Animal Care and Use Committee of Children’s Hospital, Boston. For cor-
neal tumor angiogenesis, LLC, LLC-GFP, and B16F10 were injected into 
the cornea, and angiogenic response was recorded as we described previ-
ously (28). 14,15-EET or vehicle osmotic pumps were implanted on the 
day of injection and changed once at 2 weeks after injection. Histological 
sections of tumors were analyzed for microvessel density was as described 
(32). EC migration assays were performed as we described (61). ECs were 
pretreated with tAUCB, TUPS, 14,15-EEZE, or vehicle for 30 minutes in 
suspension. VEGF was measured by ELISA as we previously described (32). 
TSP1 was measured by ELISA. Tumor cells (human prostate PC3M-LN4 
cells), ECs (human microvascular ECs [HMVECs]), or fibroblasts (human) 
were plated at 20,000 cells per well and 24 hours later were treated with 
14,15-EET (1 μM) or vehicle every 8 hours for 24 hours. Medium was col-
lected 24 hours after drug challenge. Quantitative RT-PCR was performed 
with the Qantitect SYBR Green RT-PCR kit (QIAGEN) using the ABI 
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7300 real-time PCR system (Applied Biosystems); cyclophilin controlled 
for complementary DNA content. The primers used were mouse VEGFR2 
(forward: 5′-GCCCTGCCTGGTCTCACTAC-3′, reverse: 5′-CAAAGCATT-
GCCCATTCGAT-3′), mouse VEGFR1 (forward: 5′-TGGCTCTACGACCT-
TAGACTG-3′, reverse: 5′-CAGGTTTGACTTGTCTGAGGTT-3′), mouse 
cyclophilin (forward: 5′-CAGACGCCACTGTCGCTTT-3′, reverse: 5′-
TGTCTTTGGAACTTTGTCTGCAA-3′).
LC-MS-MS analysis. Aortic ECs were isolated from WT, Tie2-CYP2J2-Tr, 
and Tie2-CYP2C8-Tr mice as previously described (62). Confluent 10-cm 
plates were treated with 10 μM A23187 for 15 minutes. Media were collect-
ed and assayed for 14,15-EET by LC/MS/MS. Kidney ECs isolated from WT 
and Tie2-sEH-Tr mice were incubated in serum-free medium for 4 hours. 
Media were collected and assayed for 14,15-EET by LC/MS/MS. Eicosanoid 
levels in plasma, tumors (TRAMP and T241 fibrosarcoma), and normal 
prostate tissue were analyzed by LC/MS/MS as previously described (19).
Statistics. Student’s 2-sided unpaired t test was used to analyze the dif-
ference between the two groups. P value less than 0.05 were considered 
statistically significant. Data are presented as mean ± SEM.
Acknowledgments
We thank and gratefully acknowledge Kristin Johnson for photog-
raphy and preparation of the figures; J. Alyce Bradbury, Joan P. 
Graves, Laura M. DeGraff, Ricky Sanchez, Lyndsay Leach, and Tony 
Walshe for excellent technical assistance; and Sung Hee Hwang for 
sEH inhibitors and eicosanoid profiling assays. We thank Isaiah J. 
Fidler for PC3M-LN4 cells. This work was supported by National 
Cancer Institute grant R01CA148633-01A1 (to D. Panigrahy); the 
Stop and Shop Pediatric Brain Tumor Fund and the C.J. Buckley 
Pediatric Brain Tumor Fund (to M.W. Kieran); Division of Intra-
mural Research of the NIH, National Institute of Environmental 
Health Sciences grants Z01 ES025034 and Z01 ES050167 (to D.C. 
Zeldin and K.B. Tomer); NIH grant R01 GM088199 (to C.R. Lee); 
the Robert A. Welch Foundation (to J.R. Falck); NIEHS Superfund 
Basic Research Program grants NIH P42 ES004699, NIH R01 
ES002710, and NIH R01 ES013933 (to B.D. Hammock); and NIH 
grant CA045548 (to D.E. Ingber). B.D. Hammock is a George and 
Judy Marcus Senior Fellow of the American Asthma Foundation.
Received for publication March 22, 2011, and accepted in revised 
form October 12, 2011.
Address correspondence to: Dipak Panigrahy, 300 Longwood Ave-
nue, Boston, Massachusetts 02115, USA. Phone: 617.919.2198; Fax: 
617.730.0231; E-mail: dipak.panigrahy@childrens.harvard.edu. Or 
to: Sui Huang, 401 Terry Avenue North, Seattle, Washington 98109, 
USA. Phone: 206.354.3569; Fax: 206.732.1299; E-mail: sui.huang@
systemsbiology.org. Or to: Mark W. Kieran, 450 Brookline Avenue, 
SW331, Boston, Massachusetts 02115, USA. Phone: 617.632.4907; 
Fax: 617.632.4897; E-mail: mark_kieran@dfci.harvard.edu. Or to: 
Darryl C. Zeldin, 111 TW Alexander Drive, Building 101, A214 
Research Triangle Park, North Carolina 27709, USA. Phone: 
919.541.1169; Fax: 919.541.4214; E-mail: zeldin@niehs.nih.gov.
 1. Gronert K. Lipid autacoids in inflammation and 
injury responses: a matter of privilege. Mol Interv. 
2008;8(1):28–35.
 2. Campbell WB, Falck JR. Arachidonic acid metabo-
lites as endothelium-derived hyperpolarizing fac-
tors. Hypertension. 2007;49(3):590–596.
 3. Fleming I. Vascular cytochrome p450 enzymes: 
physiology and pathophysiology. Trends Cardiovasc 
Med. 2008;18(1):20–25.
 4. Imig JD, Hammock BD. Soluble epoxide hydrolase 
as a therapeutic target for cardiovascular diseases. 
Nat Rev Drug Discov. 2009;8(10):794–805.
 5. Shen HC. Soluble epoxide hydrolase inhibitors: a pat-
ent review. Expert Opin Ther Pat. 2010;20(7):941–956.
 6. Munzenmaier DH, Harder DR. Cerebral microvas-
cular endothelial cell tube formation: role of astro-
cytic epoxyeicosatrienoic acid release. Am J Physiol 
Heart Circ Physiol. 2000;278(4):H1163–H1167.
 7. Pozzi A, et al. Characterization of 5,6- and 8,9-
epoxyeicosatrienoic acids (5,6- and 8,9-EET) as 
potent in vivo angiogenic lipids. J Biol Chem. 2005; 
280(29):27138–27146.
 8. Wang Y, et al. Arachidonic acid epoxygenase metab-
olites stimulate endothelial cell growth and angio-
genesis via mitogen-activated protein kinase and 
phosphatidylinositol 3–kinase/Akt signaling path-
ways. J Pharmacol Exp Ther. 2005;314(2):522–532.
 9. Panigrahy D, Kaipainen A, Greene ER, Huang S. 
Cytochrome P450-derived eicosanoids: the neglect-
ed pathway in cancer. Cancer Metastasis Rev. 2010; 
29(4):723–735.
 10. Jiang JG, et al. Cytochrome P450 2J2 promotes the 
neoplastic phenotype of carcinoma cells and is 
up-regulated in human tumors. Cancer Res. 2005; 
65(11):4707–4715.
 11. Jiang JG, et al. Cytochrome p450 epoxygenase pro-
motes human cancer metastasis. Cancer Res. 2007; 
67(14):6665–6674.
 12. Jernstrom H, Bageman E, Rose C, Jonsson PE, 
Ingvar C. CYP2C8 and CYP2C9 polymorphisms in 
relation to tumour characteristics and early breast 
cancer related events among 652 breast cancer 
patients. Br J Cancer. 2009;101(11):1817–1823.
 13. Zagorac D, Jakovcevic D, Gebremedhin D, Harder 
DR. Antiangiogenic effect of inhibitors of cyto-
chrome P450 on rats with glioblastoma multiforme. 
J Cereb Blood Flow Metab. 2008;28(8):1431–1439.
 14. Node K, et al. Anti-inflammatory properties of cyto-
chrome P450 epoxygenase–derived eicosanoids. Sci-
ence. 1999;285(5431):1276–1279.
 15. Lee CR, et al. Endothelial expression of human 
cytochrome P450 epoxygenases lowers blood pres-
sure and attenuates hypertension-induced renal 
injury in mice. FASEB J. 2010;24(10):3770–3781.
 16. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, 
Gonzalez FJ. Targeted disruption of soluble epox-
ide hydrolase reveals a role in blood pressure regu-
lation. J Biol Chem. 2000;275(51):40504–40510.
 17. Seubert JM, et al. Role of soluble epoxide hydrolase 
in postischemic recovery of heart contractile func-
tion. Circ Res. 2006;99(4):442–450.
 18. Edin ML, et al. Endothelial expression of human 
cytochrome P450 epoxygenase CYPC8 increases sus-
ceptibility to ischemia-reperfusion injury in the iso-
lated mouse heart. FASEB J. 2011;25(10):3436–3447.
 19. Newman JW, Watanabe T, Hammock BD. The simul-
taneous quantification of cytochrome P450 depen-
dent linoleate and arachidonate metabolites in urine 
by HPLC-MS/MS. J Lipid Res. 2002;43(9):1563–1578.
 20. Pettaway CA, et al. Selection of highly metastatic 
variants of different human prostatic carcinomas 
using orthotopic implantation in nude mice. Clin 
Cancer Res. 1996;2(9):1627–1636.
 21. Jeet V, Russell PJ, Khatri A. Modeling prostate can-
cer: a perspective on transgenic mouse models. Can-
cer Metastasis Rev. 2010;29(1):123–142.
 22. Almog N. Molecular mechanisms underlying tumor 
dormancy. Cancer Lett. 2010;294(2):139–146.
 23. Goss PE, Chambers AF. Does tumour dormancy 
offer a therapeutic target? Nat Rev Cancer. 2010; 
10(12):871–877.
 24. Naumov GN, et al. A model of human tumor dor-
mancy: an angiogenic switch from the nonangiogen-
ic phenotype. J Natl Cancer Inst. 2006;98(5):316–325.
 25. Holmgren L, O’Reilly MS, Folkman J. Dormancy of 
micrometastases: balanced proliferation and apop-
tosis in the presence of angiogenesis suppression. 
Nat Med. 1995;1(2):149–153.
 26. Almog N, et al. Prolonged dormancy of human 
liposarcoma is associated with impaired tumor 
angiogenesis. FASEB J. 2006;20(7):947–949.
 27. Naumov GN, MacDonald IC, Chambers AF, Groom 
AC. Solitary cancer cells as a possible source of tumour 
dormancy? Semin Cancer Biol. 2001;11(4):271–276.
 28. Kaipainen A, et al. PPARalpha deficiency in inflam-
matory cells suppresses tumor growth. PLoS One. 
2007;2(2):e260.
 29. De Palma M, et al. Tumor-targeted interferon-alpha 
delivery by Tie2-expressing monocytes inhibits 
tumor growth and metastasis. Cancer Cell. 2008; 
14(4):299–311.
 30. Zeisberger SM, Odermatt B, Marty C, Zehnder-
Fjällman AH, Ballmer-Hofer K, Schwendener 
RA. Clodronate-liposome-mediated depletion of 
tumour-associated macrophages: a new and highly 
effective antiangiogenic therapy approach. Br J Can-
cer. 2006;95(3):272–281.
 31. O’Reilly MS, et al. Angiostatin: a novel angiogen-
esis inhibitor that mediates the suppression of 
metastases by a Lewis lung carcinoma. Cell. 1994; 
79(2):315–328.
 32. Panigrahy D, et al. PPARgamma ligands inhibit pri-
mary tumor growth and metastasis by inhibiting 
angiogenesis. J Clin Invest. 2002;110(7):923–932.
 33. Parhar RS, Lala PK. Amelioration of B16F10 mela-
noma lung metastasis in mice by a combination 
therapy with indomethacin and interleukin 2. J Exp 
Med. 1987;165(1):14–28.
 34. Barbera–Guillem E, Smith I, Weiss L. Cancer-cell traf-
fic in the liver. I. Growth kinetics of cancer cells after 
portal–vein delivery. Int J Cancer. 1992;52(6):974–977.
 35. Price JE, Tarin D, Fidler IJ. Influence of organ micro-
environment on pigmentation of a metastatic murine 
melanoma. Cancer Res. 1988;48(8):2258–2264.
 36. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock 
BD. Orally bioavailable potent soluble epoxide hydro-
lase inhibitors. J Med Chem. 2007;50(16):3825–3840.
 37. Gauthier KM, et al. 14,15-Epoxyeicosa-5(Z)-enoic 
acid: a selective epoxyeicosatrienoic acid antagonist 
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 122   Number 1   January 2012 191
that inhibits endothelium-dependent hyperpolar-
ization and relaxation in coronary arteries. Circ Res. 
2002;90(9):1028–1036.
 38. Gauthier KM, Jagadeesh SG, Falck JR, Campbell 
WB. 14,15-epoxyeicosa-5(Z)-enoic-mSI: a 14,15- 
and 5,6-EET antagonist in bovine coronary arter-
ies. Hypertension. 2003;42(4):555–561.
 39. Deng Y, et al. Endothelial CYP epoxygenase overex-
pression and soluble epoxide hydrolase disruption 
attenuate acute vascular inflammatory responses 
in mice. FASEB J. 2011;25(2):703–713.
 40. Iliff JJ, Wang R, Zeldin DC, Alkayed NJ. Epoxyeico-
sanoids as mediators of neurogenic vasodilation 
in cerebral vessels. Am J Physiol Heart Circ Physiol. 
2009;296(5):H1352–H1363.
 41. Motoki A, et al. Soluble epoxide hydrolase inhibition 
and gene deletion are protective against myocardial 
ischemia-reperfusion injury in vivo. Am J Physiol 
Heart Circ Physiol. 2008;295(5):H2128–H2134.
 42. Webler AC, et al. Epoxyeicosatrienoic acids are 
part of the VEGF-activated signaling cascade lead-
ing to angiogenesis. Am J Physiol Cell Physiol. 2008; 
295(5):C1292–C1301.
 43. Gross GJ, et al. Effects of the selective EET antag-
onist, 14,15-EEZE, on cardioprotection pro-
duced by exogenous or endogenous EETs in the 
canine heart. Am J Physiol Heart Circ Physiol. 2008; 
294(6):H2838–H2844.
 44. Hanahan D, Folkman J. Patterns and emerging 
mechanisms of the angiogenic switch during 
tumorigenesis. Cell. 1996;86(3):353–364.
 45. Hicklin DJ, Ellis LM. Role of the vascular endothelial 
growth factor pathway in tumor growth and angio-
genesis. J Clin Oncol. 2005;23(5):1011–1027.
 46. Shibuya M, Claesson-Welsh L. Signal transduction by 
VEGF receptors in regulation of angiogenesis and lym-
phangiogenesis. Exp Cell Res. 2006;312(5):549–560.
 47. Kuo CJ, et al. Comparative evaluation of the anti-
tumor activity of antiangiogenic proteins deliv-
ered by gene transfer. Proc Natl Acad Sci U S A. 2001; 
98(8):4605–4610.
 48. Streit M, et al. Overexpression of thrombospondin-1 
decreases angiogenesis and inhibits the growth of 
human cutaneous squamous cell carcinomas. Am J 
Pathol. 1999;155(2):441–452.
 49. Fukumura D, et al. Tumor induction of VEGF 
promoter activity in stromal cells. Cell. 1998; 
94(6):715–725.
 50. Maharaj AS, Saint-Geniez M, Maldonado AE, 
D’Amore PA. Vascular endothelial growth fac-
tor localization in the adult. Am J Pathol. 2006; 
168(2):639–648.
 51. Enayetallah AE, French RA, Grant DF. Distribution 
of soluble epoxide hydrolase, cytochrome P450 
2C8, 2C9 and 2J2 in human malignant neoplasms. 
J Mol Histol. 2006;37(3–4):133–141.
 52. Dudley AC, et al. Calcification of multipotent prostate 
tumor endothelium. Cancer Cell. 2008;14(3):201–211.
 53. Nakamura T, Kuwai T, Kim JS, Fan D, Kim SJ, 
Fidler IJ. Stromal metalloproteinase-9 is essential 
to angiogenesis and progressive growth of ortho-
topic human pancreatic cancer in parabiont nude 
mice. Neoplasia. 2007;9(11):979–986.
 54. Pietramaggiori G, Scherer SS, Alperovich M, Chen B, 
Orgill DP, Wagers AJ. Improved cutaneous healing 
in diabetic mice exposed to healthy peripheral circu-
lation. J Invest Dermatol. 2009;129(9):2265–2274.
 55. Folkman J. Angiogenesis. In: Braunwald E, Fauci AS, 
Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. 
Harrison’s Textbook of Internal Medicine. New York, 
New York, USA: McGraw-Hill; 2001:517–530.
 56. Harach HR, Fransilla KO, Wasenius VM. Occult pap-
illary carcinoma of the thyroid. A “normal” finding 
in Finland. A systemic autopsy study. Cancer. 1985; 
56(3):531–538.
 57. Barkan D, Green JE, Chambers AF. Extracellular 
matrix: a gatekeeper in the transition from dor-
mancy to metastatic growth. Eur J Cancer. 2010; 
46(7):1181–1188.
 58. Schlaeger TM, et al. Uniform vascular–endothelial–
cell–specific gene expression in both embryonic 
and adult transgenic mice. Proc Natl Acad Sci U S A. 
1997;94(7):3058–3063.
 59. Adini A, Fainaru O, Udagawa T, Connor KM, Folk-
man J, D’Amato RJ. Matrigel cytometry: a novel 
method for quantifying angiogenesis in vivo. J Immu-
nol Methods. 2009;342(1–2):78–81.
 60. Panigrahy D, et al. PPARalpha agonist fenofibrate 
suppresses tumor growth through direct and indi-
rect angiogenesis inhibition. Proc Natl Acad Sci U S A. 
2008;105(3):985–990.
 61. Short SM, Derrien A, Narsimhan RP, Lawler J, Ing-
ber DE, Zetter BR. Inhibition of endothelial cell 
migration by thrombospondin-1 type-1 repeats 
is mediated by beta1 integrins. J Cell Biol. 2005; 
168(4):643–653.
 62. Lim YC, et al. Heterogeneity of endothelial cells 
from different organ sites in T-cell subset recruit-
ment. Am J Pathol. 2003;162(5):1591–1601.
